Recent studies have suggested that MCL-1 mainly contributes to chemotherapy resistance in ABC-DLBCL; however, ABT-737 and ABT 263 were unable to downregulate MCL-1.33,34 GX15-070, a pan-BCL-2 inhibitor, inactivates MCL-1 but causes dose-dependent thrombocytopenia.35 Therefore, seeking for the novel small-molecule inhibitors that have efficacy to both ABC- and GCB-DLBCL cells or potential to be combined with chemotherapy should be an alternative strategy to reverse relapsed/refractory for DLBCL patients. Here, BCL2 is linked to Thrombocytopenia.